Publications by authors named "Lubos E"
Background: Transcatheter tricuspid valve intervention (TTVI) has been increasingly adopted in recent years for the treatment of patients with tricuspid regurgitation (TR). However, no dedicated risk stratification has been established for patients undergoing TTVI.
Objectives: The aim of the present study was to propose a dedicated risk score for patients affected by severe TR undergoing TTVI.
Article Synopsis
- A study in Germany compared two treatments for heart failure patients with secondary mitral regurgitation: transcatheter edge-to-edge repair and surgical mitral-valve repair or replacement.
- The trial involved 210 patients and assessed outcomes like death, hospitalizations, and major adverse events, finding that transcatheter repair had similar efficacy but significantly fewer safety issues than surgery.
- Results showed that transcatheter edge-to-edge repair was noninferior to the surgical approach, indicating it might be a safer alternative for this patient group.
Article Synopsis
- Doctors are studying how a procedure called transcatheter tricuspid valve interventions (TTVI) affects patients with heart issues, specifically focusing on something called mitral regurgitation (MR) after the procedure.
- They looked at data from a big group of patients and found that many showed improvement in MR after the procedure, but some got worse.
- They discovered that certain factors, like successful procedures and specific treatments, could help predict whether a patient’s MR would improve or get worse after TTVI.
Article Synopsis
- This study investigates how intraprocedural residual mitral regurgitation (rMR) and mean mitral valve gradient (MPG) affect outcomes for patients with primary mitral regurgitation (MR) undergoing transcatheter edge-to-edge repair (TEER).
- Researchers analyzed data from 1,509 patients in the PRIME-MR registry, focusing on differences in 2-year outcomes based on the severity of rMR and MPG levels.
- Results indicated that higher levels of rMR (≥2+) were linked to worse clinical outcomes, while MPG did not significantly impact patient prognosis after the procedure.
Background: Severe tricuspid regurgitation (TR) is known to be associated with poor quality of life and increased risk of death when left untreated.
Objectives: We sought to report the 1-year clinical outcomes of subjects treated by tricuspid transcatheter edge-to-edge repair (TEER) with the TriClip system (Abbott Cardiovascular) in a contemporary real-world setting.
Methods: The bRIGHT (An Observational Real-World Study Evaluating Severe Tricuspid Regurgitation Patients Treated With the Abbott TriClip Device) postapproval study is a prospective, single-arm, open-label, multicenter postmarket registry conducted at 26 sites in Europe, with central event adjudication and echocardiographic core-laboratory assessment.
Article Synopsis
- * It found that patients with mild residual TR had an 85% survival rate, while those with moderate and severe TR had significantly lower rates of 70% and 44%, respectively.
- * The research emphasizes the need for a more detailed classification of TR severity to better predict patient outcomes and highlights the goal of achieving at least mild to moderate residual TR for successful interventions.
Mitral Valve Transcatheter Edge-to-Edge Repair: 1-Year Outcomes From the MiCLASP Study.
JACC Cardiovasc Interv
April 2024
Background: Mitral transcatheter edge-to-edge repair (M-TEER) is a guideline-recommended treatment option for patients with severe symptomatic mitral regurgitation (MR). Outcomes with the PASCAL system in a post-market setting have not been established.
Objectives: The authors report 30-day and 1-year outcomes from the MiCLASP (Transcatheter Repair of Mitral Regurgitation with Edwards PASCAL Transcatheter Valve Repair System) European post-market clinical follow-up study.
Article Synopsis
- The study examines the effectiveness of the TRI-SCORE in predicting outcomes for patients undergoing transcatheter tricuspid valve intervention (TTVI), using data from a large, international registry called TriValve.
- Among the 634 patients analyzed, those with a TRI-SCORE of 8 or higher were found to have a significantly increased risk of all-cause mortality and complications within 30 days of the procedure, compared to those with lower TRI-SCOREs.
- Despite indicating a higher risk for severe outcomes, the TRI-SCORE overall showed limited effectiveness in predicting clinical results following TTVI, as improvements in patient functional class were observed across all TRI-SCORE levels.
Aims: T-TEER is an effective therapy for the treatment of tricuspid regurgitation (TR). However, the effects of leaflets clipping on tricuspid valve annulus (TA) have not been investigated in detail. The aim of this study is to investigate the effects of tricuspid transcatheter edge-to-edge repair (T-TEER) on TA diameter.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to compare the characteristics and outcomes of patients with atrial STR (ASTR) and ventricular STR (VSTR) who underwent transcatheter edge-to-edge repair (T-TEER) for tricuspid regurgitation (TR).
- Patients were categorized into ASTR or VSTR based on specific cardiac criteria, and a total of 298 were included in the analysis, with similar procedural success rates for both groups.
- Results showed that while T-TEER effectively reduced TR in both ASTR and VSTR patients, survival rates at 12 months were significantly higher for ASTR (91%) compared to VSTR (72%).
Background: Severe tricuspid regurgitation (TR) is known to be associated with substantial morbidity and mortality.
Objectives: The authors sought to study the acute outcomes of subjects treated by tricuspid transcatheter edge-to-edge repair with the TriClip system (Abbott) in a contemporary, real-world setting.
Methods: The bRIGHT (An Observational Real-World Study Evaluating Severe Tricuspid Regurgitation Patients Treated With the Abbott TriClip™ Device) postapproval study is a prospective, single-arm, open-label, multicenter, postmarket registry conducted at 26 sites in Europe.
Background: Anaemia and iron deficiency (ID) are independently associated with adverse outcomes in patients with cardiovascular diseases, especially in those with heart failure. Here, we aimed to clarify the long-term effect of anaemia and ID on outcomes in patients undergoing transcatheter mitral edge-to-edge repair (TEER) for relevant mitral regurgitation (MR) as well as to relate these to the underlying MR aetiology.
Methods: 833 patients (median age 77.
Aims: The impact of the cardio-hepatic syndrome (CHS) on outcomes in patients undergoing mitral valve transcatheter edge-to-edge repair (M-TEER) for relevant mitral regurgitation (MR) is unknown. The objectives of this study were three-fold: (i) to characterize the pattern of hepatic impairment, (ii) to investigate the prognostic value of CHS, and (iii) to evaluate the changes in hepatic function after M-TEER.
Methods And Results: Hepatic impairment was quantified by laboratory parameters of liver function.
Article Synopsis
- This study examines the relationship between tricuspid valve gradient (TVG) and clinical outcomes in patients who underwent tricuspid transcatheter edge-to-edge repair (TEER) for significant tricuspid regurgitation.
- Researchers analyzed data from 308 patients and categorized them into quartiles based on their mean TVG at discharge.
- The results showed no significant differences in mortality or heart failure hospitalizations across the TVG quartiles one year post-procedure, indicating that higher discharge TVG was not linked to worse outcomes.
Background: Patients undergoing left atrial appendage (LAA) occlusion (LAAO) are multi-morbid, including mitral valve disease (MVD) which is associated with anatomic changes of the left atrium (LA). This study aims to identify how atrial myopathy in MVD influences outcomes in LAAO.
Methods: Atrial myopathy in MVD was defined as LA diameter > 45 mm (♀) and > 48 mm (♂) and existing MVD or history of surgical/interventional treatment.
Transcatheter valve repair of tricuspid regurgitation with the PASCAL system: TriCLASP study 30-day results.
Catheter Cardiovasc Interv
December 2022
Background: Severe tricuspid regurgitation (TR) is independently associated with increased morbidity and mortality. Percutaneous transcatheter approaches may offer an alternative for patients not amenable to surgery.
Methods: TriCLASP is a prospective, single-arm, multicenter European post-market clinical follow-up study (NCT04614402) to evaluate the safety and performance of the PASCAL system (Edwards Lifesciences) in patients with severe or greater TR.
Background: Body surface area (BSA) has been reported to be the stronger predictor for prognosis than body mass index in heart failure (HF) patients. The sex-specific association of BSA with mortality has been unclear.
Methods: EuroSMR, a European multicenter registry, included patients who underwent edge-to-edge repair (TEER) for secondary mitral regurgitation (SMR).
Aims: Right ventricular dysfunction (RVD), as expressed by right ventricular to pulmonary artery coupling, has recently been identified as a strong outcome predictor in patients undergoing mitral valve edge-to-edge repair (M-TEER) for secondary mitral regurgitation (MR). The aim of this study was to define RVD in patients undergoing M-TEER for primary MR (PMR) and to evaluate its impact on procedural MR reduction, symptomatic development and 2-year all-cause mortality.
Methods And Results: This multicentre study included patients undergoing M-TEER for symptomatic PMR at nine international centres.
Transcatheter Mitral Valve Repair in Patients With Atrial Functional Mitral Regurgitation.
JACC Cardiovasc Imaging
November 2022
Background: Among patients with severe functional mitral regurgitation (FMR), atrial functional mitral regurgitation (aFMR) represents an underrecognized entity. Data regarding outcomes after mitral valve transcatheter edge-to-edge repair (M-TEER) in aFMR remain scarce.
Objectives: The objective of this study was to analyze the outcome of aFMR patients undergoing M-TEER.
Objectives: The aim of this study was to investigate the adverse impact of elevated postprocedural mitral valve pressure gradient (MPG) on outcome in a real-world population of patients with severe mitral regurgitation (MR) who underwent transcatheter mitral valve edge-to-edge repair (TEER).
Background: TEER has become a routine treatment alternative for patients with severe MR at high surgical risk. The consequences of elevated MPG after TEER have been subject to controversial debates.
Background: Patients with severe tricuspid regurgitation present late and are often ineligible for surgery or transcatheter repair systems. Transfemoral venous implantation of a bicaval valved stent has been proposed as therapeutic option in selected patients. The aim of this study was to summarize the early procedural and clinical outcomes of the novel TRICENTO system for the treatment of patients with symptomatic severe tricuspid regurgitation.
View Article and Find Full Text PDFArticle Synopsis
- The study examined the relationship between right ventricular (RV) and pulmonary arterial (PA) function, focusing on how effectively the RV works against the pressure in the PA in patients with tricuspid regurgitation (TR) undergoing valve repair or replacement.
- Researchers measured the RV-PA coupling ratio by using echocardiograms before and after the procedure, with a key focus on the impact of this ratio on 1-year mortality.
- Findings showed that a higher RV-PA coupling ratio was linked to lower mortality rates, indicating that improved RV function is crucial for better outcomes post-surgery in patients with TR.
Article Synopsis
- Patients undergoing left atrial appendage closure (LAAC) often have severe anemia, affecting 22.3% of a study group, but this does not impact the success rate of the procedure or lead to more in-hospital complications.
- Anemic patients were generally older and had more health issues, reflected in higher risk scores, yet had significantly lower rates of severe complications during their hospital stay compared to non-anemic patients.
- Despite the lower in-hospital complication rates, anemic patients experienced higher one-year mortality mainly due to existing co-morbidities, suggesting the need for careful monitoring in this population.